QN-023a is under clinical development by Hangzhou Qihan Biotechnology and currently in Phase I for Refractory Acute Myeloid Leukemia. According to GlobalData, Phase I drugs for Refractory Acute Myeloid Leukemia have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how QN-023a’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
QN-023a is under development for the treatment of relapsed or refractory acute myeloid leukemia (AML). The therapeutic candidate comprises allogeneic NK cells genetically engineered to express chimeric antigen receptors (CAR-NK) targeting cells CD33.
Hangzhou Qihan Biotechnology overview
Hangzhou Qihan Biotechnology is a healthcare company. The company develops gene-editing organ transplantation technology. The company is Headquartered in China.
For a complete picture of QN-023a’s drug-specific PTSR and LoA scores, buy the report here.